Zobrazeno 1 - 2
of 2
pro vyhledávání: '"E Aguilar-Valle"'
Autor:
JM Fernández-Ovies, C Estaun-Martinez, I Moya-Carmona, R Mora-Santiago, E Aguilar-Valle, M Pedrosa-Ruiz
Publikováno v:
Clinical pharmacy.
Background The introduction of PCSK9 inhibitors in the treatment of hypercholesterolaemia marks a breakthrough for patients unresponsive to traditional treatment. However, in our country, 44.9% of adults have high LDL-C levels (≥ 130 mg/dL or under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa06d303c80567ed76c8d99977286ff8
https://doi.org/10.1136/ejhpharm-2017-000640.195
https://doi.org/10.1136/ejhpharm-2017-000640.195
Autor:
Mdr Mora-Santiago, Y Dominguez-Rivas, E Aguilar-Valle, L Dani-Ben-Abdel-Lah, C Estaun-Martinez, JM Fernández-Ovies, E Sánchez-Yañez, M Pedrosa-Ruiz, I Moya-Carmona
Publikováno v:
Clinical pharmacy.
Background Macitentan is a new endothelin receptor antagonist (ERA) which was compared with placebo in the SERAPHIN trial. The results showed no superior efficacy or safety compared (indirectly) with other ERAs but better hepatic tolerance. Purpose T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b018aad7ef1546c3c56bbb2a565d7a40
https://doi.org/10.1136/ejhpharm-2017-000640.128
https://doi.org/10.1136/ejhpharm-2017-000640.128